Research Topics
Species | David C HendersonSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Schizophrenia and comorbid metabolic disordersDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 66:11-20. 2005..With proper awareness and cooperation on the part of the medical community, caregivers, and patients, the detrimental consequences that may result from the metabolic disorders addressed in this article can be at least partially offset...
Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Psychiatry Res 159:140-6. 2008..Evaluating PTSD in patients with schizophrenia could have important implications from both clinical and research perspectives...- Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysisDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Boston, USA
J Clin Psychiatry 67:789-97. 2006..Much less is known regarding other agents such as quetiapine. The objective of this study was to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism... - Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patientsDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
J Clin Psychopharmacol 29:165-9. 2009..087). The addition of aripiprazole to a stable dose of olanzapine was well tolerated and resulted in significant improvements on several outcome measures that predict risk for medical morbidity... - Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophreniaDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
Hum Psychopharmacol 24:225-32. 2009.... - Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidoneDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA USA
Ann Clin Psychiatry 22:33-42. 2010..The goal of this study was to understand the relationship between clozapine and risperidone with glucose and lipid metabolism and dietary fat intake in patients with schizophrenia... - Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic studyDavid C Henderson
Schizophrenia Program, MGH Weight Center, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 66:1116-21. 2005..The goal of this 10-year naturalistic study was to examine, in clozapine-treated patients, the change in cardiovascular risk factors following clozapine initiation and the mortality estimates from cardiovascular disease... - Independent effects of tobacco abstinence and bupropion on cognitive function in schizophreniaA Eden Evins
Schizophrenia Program, the Tobacco Treatment and Research Center, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 66:1184-90. 2005.... - Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trialOliver Freudenreich
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
J Clin Psychiatry 70:1674-80. 2009..Clozapine-induced sedation can worsen cognition and impair social and occupational functioning... 
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapineDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Psychiatr Pract 15:251-61. 2009....- A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophreniaA Eden Evins
Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02144, USA
J Clin Psychopharmacol 27:380-6. 2007.... - Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
Schizophr Res 118:211-7. 2010..The present study examined whether white blood cell count (WBC), a marker of systemic inflammation, is associated with metabolic syndrome and psychiatric symptoms in non-diabetic patients with schizophrenia... - Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophreniaDavid C Henderson
Massachusetts General Hospital Schizophrenia Program, 25 Staniford Street, 2nd Floor, Boston, MA 02114, USA
Schizophr Res 130:53-6. 2011..Modafinil has been proposed as a treatment for clozapine-induced sedation and metabolic abnormalities... - A placebo-controlled study of sildenafil effects on cognition in schizophreniaDonald C Goff
Department of Psychiatry, MGH Schizophrenia Program, Freedom Trail Clinic, Massachusetts General Hospital, Harvard Medical School, 25 Staniford St, 2nd Floor, Boston, MA, 02114, USA
Psychopharmacology (Berl) 202:411-7. 2009..In addition, neuronal nitric oxide synthase, another component of the NMDA/nitric oxide/cGMP intracellular pathway, has been reported to be dysregulated in schizophrenia patients... - Higher fasting serum insulin is associated with increased resting energy expenditure in nondiabetic schizophrenia patientsXiaoduo Fan
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts 02114, USA
Biol Psychiatry 60:1372-7. 2006..This study examined the relationship between fasting serum insulin level and resting energy expenditure (REE) in a cross-sectional sample of nondiabetic schizophrenia patients... - A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainDavid C Henderson
Schizophrenia Program, Weight Center, Endocrine Unit, and Biostatistics Center, Massachusetss General Hospital, Boston, USA
Am J Psychiatry 162:954-62. 2005..This study examined the effectiveness of sibutramine, an approved weight loss agent, in overweight and obese subjects taking olanzapine for schizophrenia or schizoaffective disorder... - A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophreniaA Eden Evins
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 012114, USA
J Clin Psychopharmacol 25:218-25. 2005..We conclude that bupropion does not worsen clinical symptoms of schizophrenia and is modestly effective for smoking cessation in patients with schizophrenia. The relapse rate is high after treatment discontinuation... - Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychoticsDavid C Henderson
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
J Clin Psychiatry 68:533-41. 2007..0-295.9; referred to as "schizophrenia patients" hereafter) treated with atypical antipsychotic agents... - Prolactin-related and metabolic adverse effects of atypical antipsychotic agentsDavid C Henderson
Department of Psychiatry, Harvard Medical School, and Schizophrenia, Diabetes, and Weight Reduction Research Program, Massachusetts General Hospital, Boston, USA
J Clin Psychiatry 69:32-44. 2008.... - Medical morbidity and mortality in schizophrenia: guidelines for psychiatristsDonald C Goff
Schizophrenia Program, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 66:183-94; quiz 147, 273-4. 2005..Psychiatrists should address this problem by adopting established strategies for prevention and intervention... - No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
J Clin Psychopharmacol 31:231-4. 2011..Whereas efficacy for cognition has not yet been established for any pharmacologic strategy in schizophrenia, an accumulating body of evidence suggests a possible beneficial role of insulin... - Dietary intake profile of patients with schizophreniaDavid C Henderson
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA, USA
Ann Clin Psychiatry 18:99-105. 2006..We performed a cross-sectional study evaluating the dietary intake of patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic agents... - Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophreniaJoshua L Roffman
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
Am J Med Genet B Neuropsychiatr Genet 147:990-5. 2008..It is plausible that cumulative effects of the MTHFR T and COMT Val alleles on intracellular methylation profiles and prefrontal dopamine transmission underlie their interactive effect on perseverative errors... - Sexual functioning, psychopathology and quality of life in patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
Schizophr Res 94:119-27. 2007..The present study was to characterize relationships among sexual functioning, schizophrenia symptoms and quality of life measures. In addition, sexual functioning was compared among patients treated with different antipsychotic agents... - Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophreniaChristina P C Borba
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
J Clin Psychopharmacol 31:653-8. 2011..We now report a randomized placebo-controlled pilot study to examine the effects of ramelteon on obesity and metabolic disturbances among subjects with schizophrenia... - Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophreniaJoshua L Roffman
Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Biol Psychiatry 63:42-8. 2008..We examined whether the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C functional polymorphisms contribute to negative symptoms... - Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Psychiatry Res 149:267-71. 2007..An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia... - Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysisDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
Arch Gen Psychiatry 62:19-28. 2005.... - Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trialOliver Freudenreich
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, 25 Staniford St, 2nd Floor, Boston, MA 02114, USA
Schizophr Res 92:90-4. 2007..Risperidone augmentation of clozapine in refractory schizophrenia has theoretical but only inconsistent support from clinical trials... - Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohortOliver Freudenreich
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, the Division of Infectious Diseases and Partners AIDS Research Center, and Harvard Medical School, Boston, MA 02114, USA
Psychosomatics 48:405-11. 2007..However, clinical experience treating HCV in schizophrenia patients is limited; in this cohort, 2 years after screening, no patient had received interferon/ribavirin treatment... - A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patientsDonald C Goff
Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
Psychopharmacology (Berl) 179:144-50. 2005..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less... - Treatment of cardiac risk factors among patients with schizophrenia and diabetesAnthony P Weiss
Department of Psychiatry, Massachusetts General Hospital, Boston, 02114, USA
Psychiatr Serv 57:1145-52. 2006..The appropriateness and effectiveness of the outpatient medical management of cardiac risk factors for patients with diabetes who had a diagnosis of schizophrenia or a related psychotic syndrome were examined... - Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophreniaXiaoduo Fan
Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
J Clin Psychiatry 72:806-12. 2011.... - Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patientDavid C Henderson
Massachusetts General Hospital Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
Ann Clin Psychiatry 17:95-7. 2005..We report a case of weight loss associated with modafinil-initiation in a clozapine-treated man with schizoaffective disorder... - Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR)Oliver Freudenreich
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, United States
Psychiatry Res 176:99-102. 2010.... - Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trialOliver Freudenreich
MGH Schizophrenia Program, Freedom Trail Clinic, Boston, MA 02114, USA
Psychopharmacology (Berl) 181:358-63. 2005..A donepezil add-on strategy might make sense in selected schizophrenia cases where a pathological process is known to affect cholinergic neurons (e.g., history of head injury or comorbid dementia)... - Impact of a metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinicIlse R Wiechers
Dept of Psychiatry, Massachusetts General Hospital, Boston, USA
Acad Psychiatry 36:118-21. 2012.... - Managing weight gain and metabolic issues in patients treated with atypical antipsychoticsDavid C Henderson
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Mass, USA
J Clin Psychiatry 69:e04. 2008.... - Inflammation and schizophreniaXiaoduo Fan
Schizophrenia Program, Massachusetss General Hospital, Boston, MA, USA
Expert Rev Neurother 7:789-96. 2007.... - Weight gain with atypical antipsychotics: evidence and insightsDavid C Henderson
Department of Psychiatry, Harvard Medical School, Boston, USA
J Clin Psychiatry 68:18-26. 2007..Additionally, the need to closely monitor patients' lifestyles and homeostatic components in order to prevent weight gain or facilitate weight loss is emphasized... - Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophreniaXiaoduo Fan
Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
Schizophr Res 86:30-5. 2006..This study was undertaken to examine whether fasting serum insulin levels are associated with the psychopathology profile in a cross-sectional sample of acutely ill non-diabetic inpatients with schizophrenia... - Sibutramine: current status as an anti-obesity drug and its future perspectivesBikash Sharma
Massachusetts General Hospital, Schizophrenia Program, Harvard Medical School, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
Expert Opin Pharmacother 9:2161-73. 2008..Despite this, there are few safe and effective pharmacological interventions for obesity. Sibutramine is a weight loss agent, for use as an adjuvant to a comprehensive program of calorie restriction, exercise and behavioral therapy... - Folate, homocysteine, and negative symptoms in schizophreniaDonald C Goff
Schizophrenia Program and Neurology Service, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 161:1705-8. 2004.... - Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophreniaJoshua L Roffman
Schizophrenia Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
Schizophr Res 92:181-8. 2007..This study examined whether schizophrenia patients homozygous for the risk allele (T/T) exhibit greater impairment in executive function, and determined the extent to which MTHFR's effects on negative symptoms underlie this relationship... - Schizophrenia and diabetesDavid C Henderson
Schizophrenia Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Int Rev Neurobiol 51:481-501. 2002 - Clozapine and hypertension: a chart review of 82 patientsDavid C Henderson
Department of Psychiatry, Harvard Medical School and the MGH Biostatistics Program, Massachusetts General Hospital, Boston, Massachusetts, USA
J Clin Psychiatry 65:686-9. 2004..In this retrospective chart review study, we examine changes in systolic and diastolic blood pressure and treatment for hypertension in clozapine-treated patients... - Considerations for inpatient versus outpatient treatment with antipsychoticsDavid C Henderson
Harvard Medical School, Boston, Massachusetts, USA
CNS Spectr 12:3-5. 2007 - Capacity building in global mental health: professional trainingGregory L Fricchione
Harvard Medical School and Pierce Global Division, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
Harv Rev Psychiatry 20:47-57. 2012..In sum, this article discusses human capacity building in global mental health, provides recommendations for training, and offers examples of recent initiatives... - Low-dose clozapine and diabetic ketoacidosisJennifer M Lafayette
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Psychosomatics 44:249-52. 2003 - Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agentsDavid C Henderson
Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
Curr Diab Rep 2:135-40. 2002..A review of the recent literature and an approach to the evaluation of risk factors to aide in the safe use of atypical antipsychotic agents in presented... - Building primary care practitioners' attitudes and confidence in mental health skills in a post-conflict society: a Cambodian exampleDavid C Henderson
Harvard Program in Refugee Trauma at Massachusetts General Hospital, Boston, Massachusetts 02138, USA
J Nerv Ment Dis 193:551-9. 2005..05). Only confidence in prescribing psychotropic medications improved from posttraining to 2-year follow-up. This study supports the feasibility of training PCPs in a culturally effective manner in a postconflict society... - Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?David C Henderson
Psychotic Disorders and Schizophrenia Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
CNS Drugs 16:77-89. 2002.... - Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reductionA Eden Evins
Harvard Medical School and the Schizophrenia Research Program, Massachusetts General Hospital, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA
J Clin Psychiatry 65:307-11; quiz 452-3. 2004.... - Psychiatric effects of traumatic brain injury events in Cambodian survivors of mass violenceRichard F Mollica
Harvard Program in Refugee Trauma, Massachusetts General Hospital, Harvard Medical School, 22 Putnam Street, Cambridge, MA 02138, USA
Br J Psychiatry 181:339-47. 2002..CONCLUSIONS: Clinical identification and treatment of traumatic brain injuries in highly traumatised populations must be maintained in order to develop a new public health model for their treatment... - Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insightOliver Freudenreich
MGH Schizophrenia Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
J Clin Psychiatry 65:1372-6. 2004.... - Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophreniaDaniel E Casey
J Clin Psychiatry 65:4-18; quiz 19-20. 2004